Company / Operating Cash Flow per Share
NovaBay Pharmaceuticals, Inc. Operating Cash Flow per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.06
FY2024
5-year range
-$3.27 / -$0.13
FY2020-FY2024
Trend
-179.6%
vs FY2023
Sector context
#116 of 210
Health Care
What the data says
At $-1.06, NovaBay Pharmaceuticals, Inc.'s operating cash flow per share ranks #116 of 210 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-8.98 in FY2015 to $-0.13 in FY2020.
Based on SEC 10-K filings.
-1.06 in FY2024.
Improved from $-3.27 to $-1.06 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#116 of 210 in Health CareTop 55% of 210This company -$1.06 Sector average $5.30
▼
-120.0% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share decreased 179.6% year-over-year.
- Ranks #116 out of 210 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2020.
- Lowest operating cash flow per share in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.06 | -179.6% |
| FY2023 | -$0.38 | +88.4% |
| FY2022 | -$3.27 | -1453.0% |
| FY2021 | -$0.21 | -56.4% |
| FY2020 | -$0.13 | +63.3% |
| FY2019 | -$0.37 | -12.2% |
| FY2018 | -$0.33 | +20.5% |
| FY2017 | -$0.41 | +87.7% |
| FY2016 | -$3.35 | +62.8% |
| FY2015 | -$8.98 | -2562.6% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026